CASI Pharmaceuticals, Inc. · OTC:CASIF

CASI Pharmaceuticals — Investor Presentation (June 2020)

20 slides from CASI Pharmaceuticals's investor presentation, June 2020

  1. Slide 1: Partnering Presentation 2020

    Partnering Presentation 2020

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to

  3. Slide 3: CASI - Key Highlights

    CASI - Key Highlights DEVELOPING AND COMMERCIALIZING INNOVATIVE THERAPEUTICS AND PHARMACEUTICAL PRODUCTS USING USA-CHINA DEVELOPMENT MODEL • Launched first commercial product EVOMELA ® in China – August 2019 • Portfolio of approved and investigational assets; growing pipeline with focus on hematolog

  4. Slide 4: Partnering with CASI – Value Proposition

    Partnering with CASI – Value Proposition A strategic partner for developing and commercializing innovative products in China, the U.S. and globally • Leverage CASI Pharmaceutical’s expertise and resources to accelerate development and commercialization of innovative products into the China and U.S./

  5. Slide 5: China Market Opportunity

    China Market Opportunity • In China, therapeutic oncology treatments grew by 23.6% to $6.3 billion in 2018 and spending has more than doubled since 2013 • New medicines launched since 2013 generated $218 million in spending in 2018 • Drugs are increasingly reaching the market faster in China as a re

  6. Slide 6: Recent Execution in Hematology Oncology Portfolio

    Recent Execution in Hematology Oncology Portfolio Launched in China for multiple myeloma transplant setting in August 2019 Acquired worldwide rights to commercialize CD19 CAR- CNCT-19 T cell therapy in June 2019 – targeting acute CD19 CAR-T lymphoblastic leukemia and non-hodgkin’s lymphoma In-licens

  7. Slide 7: Active Pipeline

    Active Pipeline INDICATION IN-LICENSED CTA FILING & PHASE 1 PHASE 2 NDA FILING REVIEW REGISTRATION TRIAL & REVIEW INVESTIGATIONAL INNOVATIVE DRUG CANDIDATE WITH GLOBAL RIGHTS CNTC19 (Autologous Anti-CD19 T-cell ther Hematological Mz INDICATION PRE-CLINICAL IND/IMPD PHASE 1 |ASE PHASE 3 CID-103 (Anti

  8. Slide 8: EVOMELA Launched in China for Multiple Myeloma

    EVOMELA® Launched in China for Multiple Myeloma • Successfully launched in mid-August 2019 • HDT + ASCT is 1st line treatment for multiple myeloma • Provides best choice of preparative regimen: • Lack of propylene glycol solvent (related to certain adverse events) • Captisol formulation is stable an

  9. Slide 9: CNCT-19: CD19 CAR-T Cell Therapy – A Validated Target

    CNCT-19: CD19 CAR-T Cell Therapy – A Validated Target • Targets CD19, a B-cell surface protein widely expressed during all phases of B-cell development and validated target for B-cell derived hematological malignancies • CD19-targeted CAR have demonstrated consistently high antitumor efficacy in chi

  10. Slide 10: CID-103: Potential Best in Class Anti-CD38 mAb

    CID-103: Potential Best in Class Anti-CD38 mAb • Exclusive global rights • IND/IMPD submitted June 2020; phase I study targeted for late 2020 or 1H2021 • Phase 1 trial for CID-103 is retargeted to start in late 2020 or 1H2021 due to the COVID-19 pandemic shut down of clinical sites, we expect to res

  11. Slide 11: ZEVALIN and MARQIBO Clinical Trial Application Approvals in China

    ZEVALIN® and MARQIBO® Clinical Trial Application Approvals in China l CD20-directed radiotherapeutic antibody indicated for treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphoma (FNHL) and patients with previously untreated follicular non-Hodgkin’s

  12. Slide 12: Other Assets

    Other Assets Octreotide Long Acting Injectable (LAI) • Exclusive China rights • Octreotide LAI formulations considered a standard of care for the treatment of acromegaly and the control of symptoms associated with certain neuroendocrine tumors; recently approved in various European countries • China

  13. Slide 13: Global Senior Management Team

    Global Senior Management Team Jim Goldschmidt, PhD, Larry Zhang, Alex Zukiwski, MD, SVP, Business President Chief Medical Officer Development Wei-Wu He, PhD Chairman and CEO Cynthia Hu, JD, Thomas Zhang, China Cissy Wang, COO (US), General Commercial GM COO (CASI China) Counsel & Secretary 13

  14. Slide 14: Commercial Team with Hematologic Oncology Specialty and Track Record

    Commercial Team with Hematologic Oncology Specialty and Track Record • Senior commercial team (VPs, Dirs, DSMs), all with more than 10 years experiences at large international Heilongjiang pharmaceutical companies Jilin IM Liaoning • 90% of employees in commercial Xinjiang BJ operations have prior e

  15. Slide 15: R&D and Manufacturing Center in Wuxi

    R&D and Manufacturing Center in Wuxi • State-of-art GMP facility currently in design and planning stage • Approximately 17.6 acres of land located in major biotech and pharmaceutical region • Over 100,000 square meters of building area • Convenient transportation to 2 airports, high speed train stat

  16. Slide 16: Business Development – Senior Team

    Business Development – Senior Team James E. Goldschmidt, Ph.D. SVP Business Development More than 25 years of senior commercial and business development experience at several public and private biopharmaceutical companies, including GSK, Wyeth/Pfizer, J&J, TetraLogic Pharmaceuticals, Macrophage Ther

  17. Slide 17: Business Development Partners

    Business Development Partners • Spectrum Pharmaceuticals • Acquired exclusive China rights for three U.S. FDA-approved marketed products: • EVOMELA® (melphalan for injection), ZEVALIN® (ibritumomab tiuxetan), MARQIBO® (vincristine sulfate LIPOSOME injection) • Black Belt Therapeutics • License agree

  18. Slide 18: CASI Recap

    CASI Recap • Launched EVOMELA® (melphalan for injection) for multiple myeloma, the only commercially available melphalan in China • Robust pipeline in hematology oncology • CID-103 (potential best in class anti-CD38 mAb) • CNCT-19 (CD19 CAR-T Cell Therapy) • ZEVALIN ® (ibritumomab tiuxetan injection

  19. Slide 19: Slide 19

  20. Slide 20: Mission-Driven Board of Directors

    Mission-Driven Board of Directors WEI-WU HE, PH.D. CEO, CASI Pharmaceuticals; IDG-ACCEL China Fund Venture Chairman & CEO Partner; Managing Director ETP Global Fund, L.P.; Chairman, OriGene Technologies, Inc. QUAN ZHOU, PH.D. Founder, Managing Director & General Partner at IDG Capital Compensation C

CASI Pharmaceuticals — Investor Presentation (June 2020) on 6ix